Skip to main content
ADMA BIOLOGICS, INC. logo

ADMA BIOLOGICS, INC. — Investor Relations & Filings

Ticker · ADMA ISIN · US0008991046 US Manufacturing
Open in API
Filings indexed 962 across all filing types
Latest filing 2019-06-07 Major Shareholding Noti…
Country US United States of America
Listing US ADMA

About ADMA BIOLOGICS, INC.

https://www.admabiologics.com/

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company that develops, manufactures, and commercializes specialty plasma-derived biologics. The company's portfolio features FDA-approved immune globulin (Ig) products for the treatment of immune-compromised patients and individuals at risk for certain infections. ADMA Biologics operates a vertically integrated manufacturing process for its specialty biologic products and utilizes a patented immunotechnology platform, which includes a proprietary microneutralization assay to measure neutralizing antibody levels in plasma. The company also offers contract manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2019
Major Shareholding Notification
2019-06-07 English
PRIMARY DOCUMENT
Director's Dealing
2019-06-07 English
Investor Presentation 2019
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated June 6, 2019. It announces that the company's CEO and CFO will present at two healthcare conferences and that the investor presentation slides are filed as an exhibit. The text explicitly refers to these as 'Investor Presentations' and mentions that the slides are attached as Exhibit 99.1. There is no detailed financial data or comprehensive report content, only an announcement of upcoming presentations and the filing of presentation slides. The document length is 3565 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as an Investor Presentation (IP).
2019-06-06 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 5, 2019, reporting the results of the Annual Meeting of Stockholders of ADMA Biologics, Inc. It details the voting outcomes on several proposals including election of directors, amendment of the certificate of incorporation, advisory votes on executive compensation, and ratification of the independent auditor. The content is focused on the official results of shareholder votes at the Annual Meeting. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document is not a full annual report, earnings release, or management discussion, but specifically the voting results from the AGM. The length (7553 characters) and detailed vote counts further support this classification.
2019-06-05 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 29, 2019. It announces upcoming investor presentations by the company's CEO and CFO at healthcare conferences in June 2019. The document includes no financial statements or detailed financial data, only a notification of events and a press release exhibit. The length is 3605 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication of earnings release, annual or quarterly report, or other detailed filings. The content fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2019-05-29 English
FORM 4 SUBMISSION
Director's Dealing
2019-05-23 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.